Colgate-Palmolive Company (CL) Sets 1-Year Low


It has change of 0.03, from 2017Q3's 0.9. The investment managers in our database now have: 28.26 million shares, up from 27.72 million shares in 2017Q3.

Sei Investments Company increased Block H & R Inc (NYSE:HRB) stake by 222,563 shares to 242,807 valued at $9.80 million in 2017Q4.

Huntington National Bank reduced its stake in Colgate-Palmolive Company (NYSE:CL) by 2.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). Arvest Trust Company sold 8,453 shares as Colgate Palmolive Co (CL)'s stock declined 7.81%. Colgate Palmolive Co now has $58.97 billion valuation. The stock decreased 2.64% or $1.89 during the last trading session, reaching $69.77. The shares were sold at an average price of $73.72, for a total transaction of $282,568.76. The stock of Colgate-Palmolive Company (NYSE:CL) has "Hold" rating given on Friday, October 27 by Stifel Nicolaus. CL underperformed the S&P 500 by 17.20%. (NASDAQ:MGNX) to report earnings on May, 2. The Group One Trading Lp holds 1.07 million shares with $44.47 million value, down from 1.17M last quarter. The company had revenue of $3.89 billion during the quarter, compared to the consensus estimate of $3.92 billion. The stock has been moved at 2.59% over the last six months and -1.55% throughout last twelve months. About 392,871 shares traded. (NYSE:FIS) has risen 17.75% since April 19, 2017 and is uptrending. People's United Financial, Inc. The firm has a market cap of $63,224.85, a price-to-earnings ratio of 25.11, a price-to-earnings-growth ratio of 2.72 and a beta of 0.74. The company was maintained on Tuesday, June 6 by Jefferies. It also develops Enoblituzumab, a monoclonal antibody, which is in Phase 1 clinical trial as monotherapy in multiple solid tumor types, as well as in combination therapy with either an anti-PD-1 antibody or an anti-CTLA-4 antibody; Flotetuzumab, a DART molecule that targets CD123 and CD3; MGD007, a DART molecule, which targets glycoprotein A33 and CD3; Duvortuxizumab, a DART molecule that targets both CD19 and CD3; MGD009, a molecule in its B7-H3 franchise; MGA012, a monoclonal antibody, which targets PD-1; MGD013, a DART molecule that enables the co-blockade with a single recombinant agent of two immune checkpoint molecules; and MGC018, a B7-H3 antibody-drug conjugate. Dafna Capital Management Llc owns 154,200 shares or 1.58% of their U.S. portfolio. Also, the number of investment professionals holding NN Inc in top ten stock positions was flat from 2 to 2 for the same number. Da Davidson And invested in 105,062 shs or 0.17% of the stock. Nuveen Asset Mngmt Limited Company, Illinois-based fund reported 45,124 shares.

During Q4 2017 the big money sentiment decreased to 0.87. Its down 0.03, from 0.9 in 2017Q3. 56 investors sold all, 444 reduced holdings as Colgate-Palmolive Company ratio turned negative. 98 funds amassed positions and 335 increased positions. Clear Harbor Asset Limited Liability Corp has invested 0.1% in Colgate-Palmolive Company (NYSE:CL). Windsor Cap Mgmt Ltd Liability holds 0.14% or 3,985 shares. $972,125 worth of Colgate-Palmolive Company (NYSE:CL) was sold by HUSTON JOHN J on Friday, February 9. Horizon Kinetics Ltd Co invested 0.01% of its portfolio in Colgate-Palmolive Company (NYSE:CL). In Friday, April 20 report Morgan Stanley maintained it with "Overweight" rating and $80 target.

Mahikeng: 'If Ramaphosa doesn't act radically, government buildings could burn'
The police's Sabata Mokgwabone says, "We're managing the crowd... here and there, we're forced to use rubber bullets". He was due to address an urgent meeting in Mahikeng at 12pm (1000 GMT) alongside other senior ANC officials.

Analysts await Colgate-Palmolive Company (NYSE:CL) to report earnings on April, 27 before the open. Colgate-Palmolive Company is a part of Consumer Goods sector and belongs to Personal Products industry. CL's free cash flow ("FCF") per share for the trailing twelve months was +0.15. 93,639 are owned by Oregon Pub Employees Retirement Fund. Bailard holds 0.34% or 72,024 shares in its portfolio. Meiji Yasuda Life Com invested in 26,434 shares or 0.27% of the stock. Barclays set a $75.00 price target on shares of Colgate-Palmolive and gave the company a "hold" rating in a research note on Thursday, March 15th. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main purchased a new position in shares of Colgate-Palmolive Company during the fourth quarter valued at $189,728,000. The insider Marsili Daniel B sold $1.40 million.

CL reached $68.23 during the last trading session after $1.54 change.Currently Colgate-Palmolive Company is downtrending after 5.65% change in last April 20, 2017. $396,561 worth of stock was sold by HICKEY DENNIS J on Tuesday, February 20. The insider Verduin Patricia sold $110,310. Also, insider Jennifer Daniels sold 902 shares of the firm's stock in a transaction on Tuesday, January 9th. Eight analysts have provided estimates for Colgate-Palmolive's earnings, with the lowest EPS estimate coming in at $0.70 and the highest estimate coming in at $0.76. During the same quarter in the previous year, the business earned $0.63 EPS. CL's profit will be $637.60M for 23.81 P/E if the $0.73 EPS becomes a reality. Arrowmark Colorado Holdg Ltd Limited Liability Company reported 8,000 shares.

Among 15 analysts covering Abiomed (NASDAQ:ABMD), 12 have Buy rating, 0 Sell and 3 Hold. Therefore 18% are positive. Abiomed had 35 analyst reports since August 4, 2015 according to SRatingsIntel. KeyBanc Capital Markets maintained the stock with "Hold" rating in Wednesday, August 23 report. The rating was maintained by Jefferies with "Buy" on Thursday, November 2. The rating was maintained by Piper Jaffray on Tuesday, October 3 with "Sell". 4,676 shs were sold by HANCOCK ELLEN M, worth $346,581. The firm earned "Buy" rating on Tuesday, November 10 by Cantor Fitzgerald. The company was maintained on Monday, October 30 by Jefferies. BNP Paribas cut shares of Colgate-Palmolive from an "outperform" rating to an "underperform" rating in a research note on Tuesday, January 30th.